{"schema":"sb.node.v1","id":"sb:e/4298733e4f1032e928c19d6b","kind":"entity","label":{"text":"lung cancer","locale":"en"},"identity":{"anchor":"label:en:lung cancer","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-09T23:33:39.923351+00:00","snapshot":"deploy 28eb973c8e78d47cd7dc1d22314686757daeda65"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":303,"separatePublishers":89,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":1,"named":12,"of":12,"basis":"receipts the entity graph keeps whose own headline names the subject, over all receipts it keeps for the subject (the door's measurement; the graph carries none of its own). Only the former are served"}},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-03-26","to":"2026-10-08","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.178: about 82% of mentions carry no typed assertion"]}},"dimensions":{"domains":["precision_medicine","auto","oncology"],"activeDays":71,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/9da9cd63a03ffa31463ac703","kind":"observation","label":"medRxiv Oncology · 2026-10-07 · Prior immune checkpoint inhibitor exposure, treatment interval, and severe hepatotoxicity with sotorasib in KRAS G12C-mutant non-small-cell lung cancer: a systematic r…","url":"https://www.medrxiv.org/content/10.64898/2026.10.05.26364739v1?rss=1"},{"id":"sb:o/a896b8936f2bc05e1df85613","kind":"observation","label":"Endpoints News · 2026-10-07 · ArriVent's lung cancer drug firmonertinib fails key late-stage trial, stock tanks","url":"https://endpoints.news/arrivents-lung-cancer-drug-firmonertinib-fails-key-late-stage-trial-stock-tanks/"},{"id":"sb:o/1d08df9eb213174b2740c6d3","kind":"observation","label":"The Well News · 2026-10-07 · Amid Navy Celebration, Don’t Overlook Lung Cancer Screening for Asbestos-Exposed Veterans","url":"https://www.thewellnews.com/opinions/amid-navy-celebration-dont-overlook-lung-cancer-screening-for-asbestos-exposed-veterans/"},{"id":"sb:o/94d7da9522f0de4ccdf94625","kind":"observation","label":"Latest Science News -- ScienceDaily · 2026-10-06 · Scientists just found a way to fight lung cancer and muscle wasting at the same time","url":"https://www.sciencedaily.com/releases/2026/10/261001214129.htm"},{"id":"sb:o/ef2b4cce1344755f559c8a03","kind":"observation","label":"Fierce Biotech · 2026-10-06 · ArriVent’s phase 3 lung cancer trial flops, sinking stock","url":"https://www.fiercebiotech.com/biotech/arrivents-phase-3-lung-cancer-trial-flops-sinking-stock"},{"id":"sb:o/e9687bb7d8251f9f02899485","kind":"observation","label":"Proc Natl Acad Sci U S A · 2026-10-05 · Chronic cigarette smoke exposure induces distinct stem cell states driving genetic driver-specific non-small cell lung cancer subtypes.","url":"https://doi.org/10.1073/pnas.2604393123"},{"id":"sb:o/cc9ccba378f36a6fed753feb","kind":"observation","label":"Inside Precision Medicine · 2026-10-03 · Plasma Epigenomic Profiling May Enable Noninvasive Subtyping of Small-Cell Lung Cancer","url":"https://www.insideprecisionmedicine.com/topics/oncology/plasma-epigenomic-profiling-may-enable-noninvasive-subtyping-of-small-cell-lung-cancer/"},{"id":"sb:o/831dac4e5fe716515db5343e","kind":"observation","label":"European Medical Journal · 2026-10-02 · Radiomic Body Composition Improves Lung Cancer Survival Prediction","url":"https://www.emjreviews.com/radiology/news/radiomic-body-composition-improves-lung-cancer-survival-prediction/"},{"id":"sb:o/3b4571728c1e3c400bf87127","kind":"observation","label":"The ASCO Post · 2026-10-02 · Annual Report to the Nation: Progress Against Lung Cancer Drives Down Cancer Mortality","url":"https://ascopost.com/news/october-2026/annual-report-to-the-nation-progress-against-lung-cancer-drives-down-cancer-mortality/"},{"id":"sb:o/901df94790a9c91573864ae0","kind":"observation","label":"The ASCO Post · 2026-10-02 · Advanced Lung Cancer Pumitamig Plus Elfetabart Drozuntecan","url":"https://ascopost.com/videos/iaslc-wclc-2026/advanced-lung-cancer-pumitamig-plus-elfetabart-drozuntecan/"}],"cursor":"c1.eyJpZCI6InNiOmUvNDI5ODczM2U0ZjEwMzJlOTI4YzE5ZDZiIiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA5VDIzOjMzOjM5LjkyMzM1MSswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity whose own headline names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with immunotherapy (90 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/27c8d6ca13365be381edf726"},{"kind":"relation","label":"co-mentioned with kras (82 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1715d936aa939769f1c32a6b"},{"kind":"relation","label":"co-mentioned with fda (69 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/0b88438c5ebcdd5e4f02e648"},{"kind":"relation","label":"co-mentioned with studie (67 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/a8aefc864d56d301e4f6a9d5"},{"kind":"relation","label":"co-mentioned with egfr (63 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/8921da480b9ae69ef69be796"},{"kind":"relation","label":"co-mentioned with colorectal cancer (56 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/559687a1770380856aadbd12"},{"kind":"relation","label":"co-mentioned with china (55 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/aaea5e17c79008c233ab7c95"},{"kind":"relation","label":"co-mentioned with ai (54 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/2f597a68beaa39309706ed77"},{"kind":"relation","label":"co-mentioned with breast cancer (53 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/44cde3a5ef1ffaf7e8dd3f01"},{"kind":"relation","label":"co-mentioned with her2 (33 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/7731e0056186ce15d4ce55f7"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/4298733e4f1032e928c19d6b","mcp":"traverse {\"id\":\"sb:e/4298733e4f1032e928c19d6b\"}","page":"/entity/lung-cancer/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/4298733e4f1032e928c19d6b\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/4298733e4f1032e928c19d6b\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/4298733e4f1032e928c19d6b\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/4298733e4f1032e928c19d6b\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}